Effect of Synagis® (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants

Korean Journal of Pediatrics

Volumn 53, Issue 3, 2010, Pages 358-363

  Park, Soo Kyoung ^a   Jung, Yu Jin ^b   Yoo, Hye Soo ^a   Ahn, So Yoon ^a   Hyun, Joo Seo ^a   Choi, Seo Hui ^a   Kim, Myo Jing ^c   Jeon, Ga Won ^d   Koo, Soo Hyun ^e   Lee, Kyung Hoon ^f   Chang, Yun Sil ^a   Park, Won Soon ^a  

^a Samsung Medical Center   (South Korea)

^b Kosin University College of Medicine   (South Korea)

^c Dong A University College of Medicine   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e School of Medicine   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Readmission; RSV; Very low birth weight

Indexed keywords

EID: 79951710213     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2010.53.3.358     Document Type: Article

References (26)

1. Chien YH, Tsao PN, Chou HC, Tang JR, Tsou KI. Rehospi talization of extremely low birth weight infants in first 2 years of life. Early Hum Dev 2002;66:33-40.
2. McCormick MC, Shapiro S, Starfield BH. Rehospitalization in the first year of life high risk survivors. Pediatrics 1980;66: 991-9.
3. Kim SJ, Chae SH, Lee JH, Kim YJ, Koo SH, Jeon GW, et al. Rehospitalization of very low birth weight infants in first year after discharge from NICU and risk factor of rehospitalization caused by respiratory illness. J Korean Soc Neonatol 2006;13: 17-23.
4. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-6.
5. Simoes EA, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J 2003;22 Suppl 2: S13-20.
6. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J 2003;22 Suppl 2:S21-32.
7. Weisman LE. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing condition. Pediatr Infect Dis J 2003;22 Suppl 2:S33-9.
8. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 2003; 22 Suppl 2:S40-5.
9. Pedersen O, Herskind AM, Kamper J, Neilsen JP, Kristensen K. Rehospitalization for respiratory syncytial virus infection in infants with extremely low gestational age or birth weight in Denmark. Acta Paediatr 2003;92:240-2.
10. Lee EA, Jeong JH, Yu ST, Lee CW, Yoon HS, Park DS, et al. Incidence and risk factors of rehospitalization with respiratory syncytial virus infection in premature infants. Korean J Pediatr 2004;47:510-4.
11. Embleton IN, Harkensee C, Mckean MC. Palivizumab for preterm infants is it worth it? Arch Dis Child Fetal Neonatal Ed 2005;90:286-9.
12. Roeckle-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:237-44.
13. Carbonell EX, Quero JJ. Recommendations for the prevention of respiratory syncytial virus infections. standards committee of the Spanish society of neonatology. board of directors of the Spanish society of neonatology. An Esp Pediatr 2000;52: 372-4.
14. The IMPACT-RSV Study Group. Palivizumab, a humanized repiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
15. Björklund LJ, Lindroth M, Polberger S, Selander B. Prophylaxis against respiratory syncytial virus in premature infants. Lancet 2000;355:235-6.
16. Vogel AM, Lennon DR, Broadbent R, Byrnes CA, Grimwood K, Mildenhall L, et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J Pediatr Child Health 2002;38:550-4.
17. McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol 2002;34:262-6.
18. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-28.
19. Handforth J, Friedland JS, Sharland M. Basic epidemiology and immunopathology of RSV in children. Paediatr Respir Rev 2000;1:210-4.
20. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. N Engl J Med 1993;329:1524-30.
21. The prevent Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
22. simoes EA, Sondheimer HM, Top FH, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133;492-9.
23. American Academy of Pediatrics, Committee on Infectious Diseases and Committee of fetus and newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112: 1442-6.
24. Morris SK, Dzolganovski B, Beyene J, Sung L. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis 2009;9: 106.
25. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. IRIS study group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003;22:823-7.
26. Kusuda S, Koizumi T, Sakai T, Fujimura M, Nishida H, Togari H. Results of clnical surveillance during the Japanese first palivizumab season in 2002-2003. Pediatr Int 2006;48: 362-8.